BioNote Inc
KRX:377740
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
3 985
6 080
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
BioNote Inc
Cost of Revenue
BioNote Inc
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioNote Inc
KRX:377740
|
Cost of Revenue
-₩101.7B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cost of Revenue
-₩1.5T
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-31%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cost of Revenue
-₩227.3B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Cost of Revenue
-₩85.3B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cost of Revenue
-₩85.6B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-23%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cost of Revenue
-₩42.2B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
BioNote Inc
Glance View
BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.
See Also
What is BioNote Inc's Cost of Revenue?
Cost of Revenue
-101.7B
KRW
Based on the financial report for Dec 31, 2023, BioNote Inc's Cost of Revenue amounts to -101.7B KRW.
What is BioNote Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 3Y
-25%
Over the last year, the Cost of Revenue growth was 27%. The average annual Cost of Revenue growth rates for BioNote Inc have been -25% over the past three years .
You don't have any saved screeners yet
